MindWalk Holdings Corp. (NASDAQ: HYFT)

ImmunoPrecise Antibodies Ltd. is an AI-driven biotherapeutic research and technology firm specializing in the discovery and development of novel drugs and biologics. The company operates at the intersection of systems biology, multi-omics modeling, and complex artificial intelligence systems, offering end-to-end services in antibody discovery and development. Its proprietary technologies integrate in silico computational methodologies with wet lab infrastructure to accelerate therapeutic development, reduce costs, and mitigate risks associated with conventional drug discovery processes.

The company generates revenue primarily through contract research organization (CRO) services, which accounted for 100% of its $24.5 million in revenue for the fiscal year ended April 30, 2025. These services include custom antigen modeling, B cell sorting, phage display library screening, antibody characterization, and protein manufacturing. Additionally, ImmunoPrecise earns revenue from project-based contracts, product sales, and cryostorage services. Its customer base spans biopharmaceutical companies, academic institutions, and research organizations seeking advanced antibody development solutions.

The company operates through the following segments:

• Antibody Production and Related Services: This segment encompasses the full spectrum of antibody discovery and development services, including in silico target analysis, wet lab antibody generation, and characterization. It leverages proprietary platforms such as B cell Select®, DeepDisplay™, and HYFT® technology to deliver customized solutions for therapeutic and diagnostic applications. The segment also includes protein manufacturing, stable cell line development, and antibody engineering services.

ImmunoPrecise holds a distinctive position within the biologics CRO industry, competing with firms such as Abveris Inc., Genovac GmbH, and Genscript Biotech Corp. Its competitive advantages lie in its hybrid model, combining AI-driven in silico analyses with wet lab capabilities, which enhances efficiency and reduces time-to-market for therapeutic candidates. The company’s proprietary technologies, including LENS ai™ and rPEx®, further differentiate it by enabling high-throughput screening and complex protein production. While competitors may possess greater financial resources or broader geographic reach, ImmunoPrecise’s focus on innovation, therapeutic expertise, and integrated service offerings positions it as a leader in niche segments of the antibody development market.

The company serves a global customer base, including biopharmaceutical companies, academic research institutions, and biotechnology firms. Key partnerships and collaborations have been established with entities such as OmniAb, Inc., BriaCell Therapeutics Corp., Astellas Pharma Inc., and Biotheus Inc. Its services cater to clients seeking advanced antibody discovery, optimization, and production for therapeutic applications, particularly in oncology, neurodegenerative diseases, and autoimmune disorders.